FDAapproval95% confidence
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (cardiology) as Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiology · Diuretic
- Sub-indication
- Hypertension
Related signal: FDA Grants AP Status for Spironolactone ANDA217761 by Annora Pharma